Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gontivimab
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Inhalation
01
Overview
Gontivimab is a trivalent Nanobody (monoclonal antibody-derived therapeutic protein) that targets the prefusion F protein of respiratory syncytial virus (RSV). It binds with high affinity to antigenic site II of the RSV F protein and acts as a virus internalisation inhibitor and virus replication inhibitor. Gontivimab was developed for inhaled administration to treat RSV infections, particularly in infants and immunocompromised adults. The drug demonstrated potent antiviral activity *in vitro* and reduced RSV load in animal models. Clinical development reached phase 2 trials but was discontinued before approval[1][3][5][7].
- Other names
- anti-RSV protein F nanobody alx-0171anti-RSV nanobody
02
Targets
RSV F site II (RSV F antigenic site II)
Beyond the preview
Go deeper on gontivimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gontivimab.